Recombinant Human Coagulation Factor Ⅷ
- Generic Name
- Recombinant Human Coagulation Factor Ⅷ
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于血浆凝血因子Ⅷ（FⅧ）缺乏的甲型血友病（罕见病）治疗。在纠正或预防出血、急诊或择期手术中，本品起到暂时代替缺失的凝血因子的作用。
- Associated Conditions
- -
- Associated Therapies
- -
Top 10 Hemophilia Stories of 2024
In 2024, Hemophilia News Today highlighted key advancements in hemophilia treatment, including gene therapies like BBM-H803 for hemophilia A, Mim8's efficacy, and the launch of Beqvez for hemophilia B. Roctavian showed significant bleeding reduction, and the FDA cleared a CRISPR therapy trial for hemophilia B, marking a year of progress in hemophilia care.
Hemophilia A Clinical Trials 2024: EMA, PDMA, FDA Approvals, Pipeline, Therapies
DelveInsight's 'Hemophilia A Pipeline Insight 2024' covers global Hemophilia A therapies, highlighting over 40+ pipeline therapies, key companies like Spark Therapeutics, Pfizer, and Sanofi, and recent FDA approvals for Roctavian and ALTUVIIIO. The report assesses the therapeutic landscape, including product types, stages, routes of administration, and molecule types.
Hemophilia A Clinical Trials 2024: EMA, PDMA, FDA Approvals
DelveInsight's 'Hemophilia A Pipeline Insight 2024' covers global Hemophilia A therapies, highlighting over 40+ pipeline therapies, key companies like Spark Therapeutics, Pfizer, and Novo Nordisk, and recent FDA approvals for Roctavian and ALTUVIIIO.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath